Chemours (NYSE:CC) Stock Rating Upgraded by Zacks Research

Chemours (NYSE:CC) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

A number of other equities analysts have also recently weighed in on CC. JPMorgan Chase & Co. lowered their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. BMO Capital Markets cut their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Alembic Global Advisors restated an “overweight” rating and set a $30.00 price target on shares of Chemours in a research report on Wednesday, May 13th. Royal Bank Of Canada dropped their price objective on Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Finally, Weiss Ratings downgraded Chemours from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Chemours has a consensus rating of “Hold” and a consensus price target of $20.10.

Chemours Stock Down 0.2%

Shares of CC opened at $15.04 on Thursday. The firm has a market cap of $2.26 billion, a P/E ratio of -7.88 and a beta of 1.42. Chemours has a 12-month low of $10.44 and a 12-month high of $28.67. The company’s 50-day moving average price is $16.39 and its 200 day moving average price is $19.64. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same period last year, the business earned ($2.54) EPS. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. On average, sell-side analysts forecast that Chemours will post 0.87 earnings per share for the current year.

Insider Activity at Chemours

In other Chemours news, CFO Shane Hostetter acquired 3,350 shares of the stock in a transaction dated Thursday, August 6th. The stock was acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the transaction, the chief financial officer owned 102,698 shares in the company, valued at $1,534,308.12. The trade was a 3.37% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the transaction, the insider owned 58,547 shares in the company, valued at approximately $909,234.91. This represents a 3.42% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 8,663 shares of company stock valued at $130,601 over the last quarter. 0.85% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CC. Atlas Capital Advisors Inc. acquired a new position in Chemours in the fourth quarter valued at $26,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Chemours in the fourth quarter valued at about $28,000. Covestor Ltd boosted its holdings in shares of Chemours by 204.7% in the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock valued at $31,000 after acquiring an additional 1,748 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in shares of Chemours during the fourth quarter worth about $31,000. Finally, Rothschild Investment LLC increased its stake in shares of Chemours by 87.0% during the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock worth $32,000 after acquiring an additional 1,255 shares during the period. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours, DuPont and Corteva agreed to pay $455 million over 15 years to resolve claims brought by North Carolina and 11 local entities involving PFAS and other historical discharges from Chemours’ Fayetteville Works plant, as well as certain AFFF-related claims. Chemours’ share is approximately $180 million on a net-present-value basis, and the company said the obligation is covered by existing accruals, limiting the immediate earnings impact. Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
• Positive Sentiment: The settlement removes a significant portion of litigation uncertainty tied to the Fayetteville Works site and clarifies future cash obligations, which investors viewed favorably. Reports indicated Chemours shares rose during the session following the announcement. Why Is Chemours Stock Trading Higher Today?
• Neutral Sentiment: Several reports describe the agreement as a $380 million settlement with 11 public entities, while other headlines cite $590 million. These figures appear to reflect different components or descriptions of the broader resolution; the companies’ announced terms identify total settlement payments of $455 million over 15 years. Chemours, DuPont, Corteva settle North Carolina forever chemicals claims for $455 million
• Negative Sentiment: The agreement still represents a substantial long-term liability and does not eliminate broader PFAS-related regulatory, cleanup or litigation risks. Chemours’ results already show pressure from weaker revenue and an earnings miss, making continued legal-cost management important for investors.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company headquartered in Wilmington, Delaware. Formed in 2015 through a spin-off from DuPont, Chemours develops and manufactures chemical products used in industries including transportation, electronics, energy, construction, and consumer goods.

The company operates through businesses focused on thermal and specialized solutions, titanium technologies, and advanced performance materials. Its products include refrigerants and heat-transfer fluids, titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper, as well as fluoropolymers, specialty fluids, and other performance materials used in demanding industrial applications.

Chemours serves customers in North America, Latin America, Europe, the Asia-Pacific region, and other international markets through manufacturing facilities, research and development operations, and commercial activities around the world.